{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T12:58:34Z","timestamp":1761742714336},"reference-count":29,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2006,4,1]],"date-time":"2006-04-01T00:00:00Z","timestamp":1143849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2006,4]]},"DOI":"10.1016\/j.ejca.2006.01.008","type":"journal-article","created":{"date-parts":[[2006,3,3]],"date-time":"2006-03-03T12:34:11Z","timestamp":1141389251000},"page":"704-707","source":"Crossref","is-referenced-by-count":52,"title":["C-reactive protein levels and subsequent cancer outcomes: Results from a prospective cohort study"],"prefix":"10.1016","volume":"42","author":[{"given":"Kathy J.","family":"Helzlsouer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas P.","family":"Erlinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth A.","family":"Platz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2006.01.008_bib1","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1093\/clinchem\/45.12.2136","article-title":"Clinical efficacy of an automated high-sensitivity C-reactive protein assay","volume":"45","author":"Rifai","year":"1999","journal-title":"Clin Chem"},{"key":"10.1016\/j.ejca.2006.01.008_bib2","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJM199704033361401","article-title":"Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men","volume":"336","author":"Ridker","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2006.01.008_bib3","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJM200003233421202","article-title":"C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women","volume":"342","author":"Ridker","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2006.01.008_bib4","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1001\/jama.291.5.585","article-title":"C-reactive protein and the risk of incident colorectal cancer","volume":"291","author":"Erlinger","year":"2004","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.ejca.2006.01.008_bib5","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/pros.10368","article-title":"No association between pre-diagnostic plasma C-reactive protein concentration and subsequent prostrate cancer","volume":"59","author":"Platz","year":"2004","journal-title":"Prostate"},{"key":"10.1016\/j.ejca.2006.01.008_bib6","unstructured":"Gunter MJ, Stolzenberg-Solomon R, Cross AJ, et al. C-reactive protein (CRP) and colorectal cancer incidence in a cohort of male smokers.Proceedings Frontiers in Cancer Prevention, Baltimore, MD, October 2005."},{"key":"10.1016\/j.ejca.2006.01.008_bib7","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1158\/1055-9965.EPI-05-0316","article-title":"Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort","volume":"14","author":"Il\u2019yasova","year":"2005","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.ejca.2006.01.008_bib8","unstructured":"Fibrinogen Studies Collaboration. Plasma fibrinogen level and the risk of major cardiovascular diseases and non-vascular mortality, an individual participant meta-analysis. JAMA 2005;294:1799\u2013809."},{"key":"10.1016\/j.ejca.2006.01.008_bib9","doi-asserted-by":"crossref","first-page":"425","DOI":"10.7326\/0003-4819-142-6-200503150-00008","article-title":"C-reactive protein levels are not associated with increased risk for colorectal cancer in women","volume":"142","author":"Zhang","year":"2005","journal-title":"Ann Intern Med"},{"issue":"Suppl. 2","key":"10.1016\/j.ejca.2006.01.008_bib10","doi-asserted-by":"crossref","first-page":"S185","DOI":"10.2188\/jea.15.S185","article-title":"Colorectal cancer and serum C-reactive protein levels: a case-control study nested in the JACC study","author":"Ito","year":"2005","journal-title":"J Epidemiol"},{"key":"10.1016\/j.ejca.2006.01.008_bib11","first-page":"1322","article-title":"Aspirin use and risk of fatal cancer","volume":"53","author":"Thun","year":"1993","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2006.01.008_bib12","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1001\/jama.294.8.914","article-title":"Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer","volume":"294","author":"Chan","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.ejca.2006.01.008_bib13","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1056\/NEJMoa021735","article-title":"A randomized trial of aspirin to prevent colorectal adenomas","volume":"348","author":"Baron","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2006.01.008_bib14","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa021633","article-title":"A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer","volume":"348","author":"Sandler","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2006.01.008_bib15","doi-asserted-by":"crossref","first-page":"713","DOI":"10.7326\/0003-4819-128-9-199805010-00003","article-title":"Aspirin use and colorectal cancer: post-trial follow-up data from the physicians\u2019 health study","volume":"128","author":"Sturmer","year":"1998","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ejca.2006.01.008_bib16","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1001\/jama.294.1.47","article-title":"Low-dose aspirin in the primary prevention of cancer. The women\u2019s health study: a randomized controlled trial","volume":"294","author":"Cook","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.ejca.2006.01.008_bib17","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1200\/JCO.2005.09.051","article-title":"COX-2: a molecular target for colorectal cancer prevention","volume":"23","author":"Brown","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2006.01.008_bib18","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1056\/NEJMe058038","article-title":"COX-2 inhibitors \u2013 a lesson in unexpected problems","volume":"352","author":"Drazen","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2006.01.008_bib19","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1056\/NEJMe058042","article-title":"COX-2 inhibitors-lessons in drug safety","volume":"352","author":"Psaty","year":"2005","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.ejca.2006.01.008_bib20","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1056\/NEJMoa050405","article-title":"Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention","volume":"352","author":"Solomon","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2006.01.008_bib21","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1056\/NEJMoa050493","article-title":"Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial","volume":"352","author":"Bresalier","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2006.01.008_bib22","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0889-8588(05)70317-8","article-title":"Intermediate markers as surrogate endpoints in cancer research","volume":"14","author":"Schatzkin","year":"2000","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.ejca.2006.01.008_bib23","doi-asserted-by":"crossref","first-page":"3S","DOI":"10.1016\/S0002-9343(98)00338-6","article-title":"Natural history of colorectal cancer","volume":"106","author":"Winawer","year":"1999","journal-title":"Am J Med"},{"key":"10.1016\/j.ejca.2006.01.008_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0889-8553(05)70280-6","article-title":"Colorectal polyps and their relationship to cancer","volume":"26","author":"Kim","year":"1997","journal-title":"Gastroenterol Clin North Am"},{"key":"10.1016\/j.ejca.2006.01.008_bib25","unstructured":"Colorectal Cancer Fact Sheet. Available from: http:\/\/www.cdc.gov\/colorectalcancer\/what_cdc_is_doing\/about_cdc_program.htm."},{"key":"10.1016\/j.ejca.2006.01.008_bib26","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","article-title":"Tamoxfen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study","volume":"90","author":"Fisher","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2006.01.008_bib27","doi-asserted-by":"crossref","first-page":"712","DOI":"10.7326\/0003-4819-126-9-199705010-00007","article-title":"Using numerical results from systematic reviews in clinical practice","volume":"126","author":"McQuay","year":"1997","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ejca.2006.01.008_bib28","unstructured":"Aspirin for the primary prevention of cardiovascular events: summary of the evidence. Article originally in Annals of Internal Medicine 2002. Rockville, MD: Agency for Healthcare Research and Quality. Available from: http:\/\/www.ahrq.gov\/clinic\/ 3rduspstf\/aspirin\/aspsum1.htm."},{"key":"10.1016\/j.ejca.2006.01.008_bib29","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1002\/cncr.20882","article-title":"Breast carcinoma chemoprevention in the community setting. Estimating risks and benefits","volume":"103","author":"Brewster","year":"2005","journal-title":"Cancer"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804906000657?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804906000657?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,13]],"date-time":"2020-04-13T00:57:43Z","timestamp":1586739463000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804906000657"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2006,4]]}},"alternative-id":["S0959804906000657"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2006.01.008","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2006,4]]}}}